Allakos Inc
NASDAQ:ALLK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
BP PLC
BMV:BPN
|
UK |
Allakos Inc
Other Current Liabilities
Allakos Inc
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Allakos Inc
NASDAQ:ALLK
|
Other Current Liabilities
$323k
|
CAGR 3-Years
-60%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Current Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Current Liabilities
$92m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-15%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Current Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Current Liabilities
$428.3m
|
CAGR 3-Years
11%
|
CAGR 5-Years
6%
|
CAGR 10-Years
30%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Current Liabilities
$553m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
13%
|
|
Allakos Inc
Glance View
Allakos, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Redwood City, California and currently employs 192 full-time employees. The company went IPO on 2018-07-19. The firm is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. The company is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. The company also developed a formulation of lirentelimab for subcutaneous (SC) administration. The firm is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.
See Also
What is Allakos Inc's Other Current Liabilities?
Other Current Liabilities
323k
USD
Based on the financial report for Dec 31, 2024, Allakos Inc's Other Current Liabilities amounts to 323k USD.
What is Allakos Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
26%
Over the last year, the Other Current Liabilities growth was -49%. The average annual Other Current Liabilities growth rates for Allakos Inc have been -60% over the past three years , 26% over the past five years .
